Haemonetics Corporation (NYSE:HAE) has earned a consensus recommendation of “Hold” from the eight brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $51.33.
HAE has been the topic of several analyst reports. TheStreet upgraded Haemonetics Corporation from a “c” rating to a “b-” rating in a report on Monday, August 7th. Jefferies Group LLC restated a “buy” rating and set a $48.00 price objective on shares of Haemonetics Corporation in a report on Thursday, July 27th. Zacks Investment Research upgraded Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a report on Wednesday, August 9th. Morgan Stanley restated an “equal weight” rating and set a $43.00 price objective (up previously from $38.00) on shares of Haemonetics Corporation in a report on Friday, October 6th. Finally, Craig Hallum reaffirmed a “hold” rating and issued a $50.00 target price (up from $40.00) on shares of Haemonetics Corporation in a research report on Wednesday, November 8th.
Several institutional investors and hedge funds have recently modified their holdings of the stock. US Bancorp DE raised its position in shares of Haemonetics Corporation by 0.6% in the 2nd quarter. US Bancorp DE now owns 22,154 shares of the medical instruments supplier’s stock worth $875,000 after buying an additional 141 shares during the period. Tudor Investment Corp ET AL raised its position in Haemonetics Corporation by 0.5% in the second quarter. Tudor Investment Corp ET AL now owns 28,126 shares of the medical instruments supplier’s stock valued at $1,111,000 after purchasing an additional 143 shares during the period. Louisiana State Employees Retirement System raised its position in Haemonetics Corporation by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 21,400 shares of the medical instruments supplier’s stock valued at $845,000 after purchasing an additional 200 shares during the period. Rothschild Asset Management Inc. raised its position in Haemonetics Corporation by 0.3% in the second quarter. Rothschild Asset Management Inc. now owns 87,858 shares of the medical instruments supplier’s stock valued at $3,470,000 after purchasing an additional 269 shares during the period. Finally, Strs Ohio raised its position in Haemonetics Corporation by 1.0% in the second quarter. Strs Ohio now owns 29,300 shares of the medical instruments supplier’s stock valued at $1,157,000 after purchasing an additional 300 shares during the period.
Shares of Haemonetics Corporation (NYSE:HAE) opened at $54.52 on Monday. Haemonetics Corporation has a fifty-two week low of $36.44 and a fifty-two week high of $55.10. The company has a current ratio of 2.17, a quick ratio of 1.72 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $2,879.64, a price-to-earnings ratio of 33.45, a PEG ratio of 4.08 and a beta of 0.91.
Haemonetics Corporation (NYSE:HAE) last posted its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.07. Haemonetics Corporation had a return on equity of 11.16% and a net margin of 0.50%. The business had revenue of $225.40 million for the quarter, compared to analysts’ expectations of $219.12 million. During the same quarter last year, the firm earned $0.38 earnings per share. The business’s revenue was up 2.3% on a year-over-year basis. research analysts expect that Haemonetics Corporation will post 1.7 EPS for the current fiscal year.
Haemonetics Corporation Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.